RxDoctor Payments Data

Jacqueline Azelvandre, DO

Family Medicine · Longwood, FLNPI 1639160831

Payments from drug & device makers

$6,352in general payments, 2019–2025

Across 332 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$922
  • Boehringer Ingelheim$662
  • Novo Nordisk$371
  • Pfizer$363
  • AbbVie$354
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,322100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,352 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$126,553
Medicare patients
298
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$59,478
MounjaroTirzepatide23$22,951
EliquisApixaban17$21,377
JardianceEmpagliflozin13$12,042
Lagevrio (Eua)Molnupiravir14$5,040
SynthroidLevothyroxine Sodium38$4,295
Levothyroxine Sodium298$2,429
Atorvastatin Calcium242$2,169
Pantoprazole Sodium76$1,596
Losartan Potassium220$1,426
Metoprolol Succinate100$1,212
Bupropion XlBupropion Hcl37$1,006
Rosuvastatin Calcium89$992
Amlodipine Besylate176$970
Albuterol Sulfate HfaAlbuterol Sulfate36$928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$371$59,47840 claims
Lilly USA, LLCMounjaro$922$22,95123 claims
PfizerEliquis$363$21,37717 claims
Boehringer IngelheimJardiance$662$12,04213 claims
MerckLagevrio (Eua)$230$5,04014 claims
AbbVieSynthroid$354$4,29538 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$2,429298 claims
Almatica Pharma LLCSertraline Hcl$13$56651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →